SK Chemicals Reports Q1 2026 Consolidated Operating Loss of KRW 18.9 Billion; Life Science Segment Continues Losses


  • Consolidated Q1 2026 revenue: KRW 655.9 billion, operating loss: KRW 18.9 billion, net loss attributable to parent: KRW 12.1 billion (swung to loss vs prior year).
  • Green Chemicals Biz. posted operating profit of KRW 15.9 billion, but Life Science Biz. recorded an operating loss of KRW 39.1 billion.
  • Approximately 10 lawsuits related to humidifier disinfectant (e.g., indemnity claims) are ongoing, with total claim amount of about KRW 117.4 billion.
  • Derivative liabilities: exchangeable bonds KRW 53.3 billion, currency forward contracts etc. KRW 0.69 billion.
  • Consolidated R&D expenditure: KRW 12.0 billion (1.8% of revenue).
  • Total assets: KRW 6.11 trillion, total liabilities: KRW 2.98 trillion, equity: KRW 3.13 trillion.
ADVERTISEMENT (250px+)

KOSPI Filing Information


  • Filing: Quarterly Report (2026.03)
  • Company: SK Chemicals (285130)
  • Submission: SK Chemicals Co., Ltd.
  • Receipt: 05-13-2026